By Stephen Nakrosis

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi said Friday the U.S. Food and Drug Administration gave its approval to Libtayo for the treatment of patients with metastatic cutaneous squamous cell carcinoma, or CSCC.

The companies said CSCC is the second most common skin cancer in the U.S.

Regeneron and Sanofi Genzyme, the specialty care global business unit of Sanofi, will market Libtayo jointly in the U.S.

Shares of Regeneron, which closed Friday trading down 0.48% at $404.04, were up slightly in after-hours trading, gaining 1.48% to $410.00.

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

September 28, 2018 17:29 ET (21:29 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Sanofi Charts.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Sanofi Charts.